Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab

Fig. 1

Relationship between Hb levels and clinical efficacy outcomes: CDAI and DAS-28 CRP over time. Slicefit plots of CDAI and DAS-28 CRP (Y-axis) against hemoglobin (g/L) (X-axis) by a visit from baseline to week 24. Patients with non-missing CRP (mg/L) and hemoglobin (g/L) values were considered. Each panel in the regression model shows the relationship between an outcome and Hb level at a given point in time, stratified by treatment. The lines, with shading, depict the treatment-specific regression coefficient (i.e., slope) and 95% CI associated with the linear regression in which Hb is the independent variable and the outcome is the dependent variable. CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DAS, Disease Activity Scores; Hb, hemoglobin; q2w, every 2 weeks

Back to article page